한글목차

세계의 표적 RNA 시퀀싱 시장 규모는 2024년에 22억 9,400만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 18.7%로 성장하여 2031년까지 77억 8,100만 달러로 확대될 것으로 예측됩니다.

표적 RNA 시퀀싱은 하이스루풋 시퀀싱을 이용하여 특정 유전자 또는 유전자 영역의 발현을 정량적으로 분석하는 분자생물학 기술입니다. 전체 전사체 염기서열 분석과 달리 표적 RNA 시퀀싱은 정의된 유전자 패널에 초점을 맞추기 때문에 저비용, 고감도, 데이터 처리의 단순화 등의 장점이 있습니다. 암 서브타이핑, 면역미세환경 프로파일링, 약물 표적 발굴, 유전성 질환 진단, 단일 세포 발현 분석 등에 널리 활용되고 있습니다. 시퀀싱 플랫폼의 보급과 다중 PCR 기술 및 프로브 하이브리데이션 기술의 발전에 따라, 표적 RNA 시퀀싱은 정밀 발현 분석 분야에서 임상 연구 기관 및 생명공학 기업에게 일상적이고 강력한 도구가 되었습니다.

맞춤형 치료의 개념이 심화되고 정밀의료가 발전함에 따라, 특히 암과 유전성 질환의 응용 분야에서 표적 RNA 시퀀싱에 대한 수요는 지속적으로 증가하고 있습니다. 정부 주도의 노력과 바이오마커 개발 및 바이오인포매틱스 분야에 대한 대형 제약사들의 지속적인 투자가 연구기관 및 상업시설의 기술 도입을 가속화하고 있습니다. 일루미나(Illumina), 써모피셔(Thermo Fisher)와 같은 기업들은 표적 시퀀싱 패널의 매출에서 20% 이상의 안정적인 CAGR을 보고하고 있으며, 이는 유전체 서비스 포트폴리오에서 그 역할이 확대되고 있음을 보여줍니다. 미국, 중국, 유럽의 생명과학 분야 국가 자금이 급증하면서 시장이 더욱 활성화되고 있습니다.

유망한 전망에도 불구하고, 시장은 복잡한 데이터 해석, 워크플로우의 표준화 부족, 샘플 조제의 기술적 민감도 등의 문제에 직면해 있습니다. 하이스루풋 시퀀싱 플랫폼은 여전히 높은 비용으로 인해 소규모 연구소나 기관에서는 도입 장벽으로 작용하고 있습니다. 또한, IVD 인증, CLIA 준수 등 규제 프레임워크가 엄격해지면서 임상 적용까지의 타임라인이 길어지고 있습니다. 경쟁 압력도 증가하고 있으며, 가격 설정이 결정적인 요인으로 작용하고 주요 업체들 사이에 협상력이 집중되고 있습니다.

다운스트림 수요는 주로 암 연구기관, 바이오제약 기업, 제3자 CRO 서비스 제공업체가 주도하고 있습니다. 암 검진, 액체 생검, 면역치료 표적 개발이 발전함에 따라 RNA 기반 동반진단에 대한 의존도가 높아지고 있습니다. 투자은행 보고서에 따르면, 표적 발현 프로파일링은 RNA 시퀀싱 시장 내 점유율을 확대하고 있으며, 향후 5년간 고형 종양 진단, 소아 희귀질환 분석, 세포 치료제 제조 품질 관리 등 고부가가치 분야로의 침투가 예상된다고 밝혔습니다.

이 보고서는 표적 RNA 시퀀싱 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

표적 RNA 시퀀싱 시장의 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출 수익으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 상황을 평가하고, 현재 시장에서의 위치를 분석하고, 표적 RNA 시퀀싱에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와주는 책입니다. 수 있도록 설계되어 있습니다.

시장 세분화

기업별

• Thermo Fisher
• Illumina
• Roche Holdings
• BGI
• Eurofins
• LabCorp
• Berry Genomics
• Macrogen
• GENEWIZ
• Natera
• Novogen
• Pacific Biosciences
• Oxford Nanopore

유형별 부문

• 엑솜 시퀀싱
• 인리치먼트 시퀀싱
• 앰플리콘 시퀀싱

용도별 부문

• 조사기관
• 병원·클리닉
• 바이오테크놀러지 기업
• 진단 검사실

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동 및 아프리카

영문목차

The global market for Targeted RNA Sequencing was estimated to be worth US$ 2294 million in 2024 and is forecast to a readjusted size of US$ 7781 million by 2031 with a CAGR of 18.7% during the forecast period 2025-2031.

Targeted RNA Sequencing is a molecular biology technique that uses high-throughput sequencing to quantitatively analyze the expression of specific genes or gene regions. Unlike whole transcriptome sequencing, targeted RNA sequencing focuses on a defined gene panel, offering advantages such as lower cost, higher sensitivity, and simplified data processing. It is widely used in cancer subtyping, immune microenvironment profiling, drug target identification, genetic disease diagnostics, and single-cell expression analysis. With the proliferation of sequencing platforms and the advancement of multiplex PCR and probe hybridization technologies, targeted RNA sequencing has become a routine and powerful tool for clinical research institutions and biotech companies in the field of precision expression analysis.

As the concept of personalized treatment deepens and precision medicine advances, demand for targeted RNA sequencing continues to grow, especially in cancer and genetic disease applications. Government initiatives and sustained investments from pharma giants in biomarker development and bioinformatics are accelerating technology adoption in research labs and commercial institutions. Companies like Illumina and Thermo Fisher have reported a consistent CAGR of over 20% in targeted sequencing panel revenues, highlighting its growing role in genomic service portfolios. National funding surges in life sciences across the U.S., China, and Europe are further energizing the market.

Despite the promising outlook, the market faces challenges such as complex data interpretation, lack of standardization in workflows, and technical sensitivity to sample preparation. High-throughput sequencing platforms remain costly, creating adoption barriers for smaller labs and institutions. Additionally, increasingly stringent regulatory frameworks (e.g., IVD certifications, CLIA compliance) have extended timelines for clinical applications. Competitive pressure is also rising, with pricing becoming a pivotal factor and bargaining power concentrated among leading players.

Downstream demand is primarily driven by cancer research institutes, biopharma companies, and third-party CRO service providers. With the rise of cancer screening, liquid biopsy, and immunotherapy target development, the reliance on RNA-based companion diagnostics is intensifying. According to investment bank reports, targeted expression profiling is expanding its share within the RNA sequencing market and is expected to penetrate high-value segments such as solid tumor diagnostics, pediatric rare disease analysis, and quality control in cell therapy manufacturing over the next five years.

This report aims to provide a comprehensive presentation of the global market for Targeted RNA Sequencing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Targeted RNA Sequencing by region & country, by Type, and by Application.

The Targeted RNA Sequencing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted RNA Sequencing.

Market Segmentation

By Company

• Thermo Fisher
• Illumina
• Roche Holdings
• BGI
• Eurofins
• LabCorp
• Berry Genomics
• Macrogen
• GENEWIZ
• Natera
• Novogen
• Pacific Biosciences
• Oxford Nanopore

Segment by Type

• Exome Sequencing
• Enrichment Sequencing
• Amplicon Sequencing

Segment by Application

• Research Institutes
• Hospitals & Clinics
• Biotechnology Company
• Diagnostic Lab

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Targeted RNA Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Targeted RNA Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Targeted RNA Sequencing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Targeted RNA Sequencing Product Introduction
• 1.2 Global Targeted RNA Sequencing Market Size Forecast (2020-2031)
• 1.3 Targeted RNA Sequencing Market Trends & Drivers
  • 1.3.1 Targeted RNA Sequencing Industry Trends
  • 1.3.2 Targeted RNA Sequencing Market Drivers & Opportunity
  • 1.3.3 Targeted RNA Sequencing Market Challenges
  • 1.3.4 Targeted RNA Sequencing Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Targeted RNA Sequencing Players Revenue Ranking (2024)
• 2.2 Global Targeted RNA Sequencing Revenue by Company (2020-2025)
• 2.3 Key Companies Targeted RNA Sequencing Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Targeted RNA Sequencing Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Targeted RNA Sequencing
• 2.6 Targeted RNA Sequencing Market Competitive Analysis
  • 2.6.1 Targeted RNA Sequencing Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Targeted RNA Sequencing Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted RNA Sequencing as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Exome Sequencing
  • 3.1.2 Enrichment Sequencing
  • 3.1.3 Amplicon Sequencing
• 3.2 Global Targeted RNA Sequencing Sales Value by Type
  • 3.2.1 Global Targeted RNA Sequencing Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Targeted RNA Sequencing Sales Value, by Type (2020-2031)
  • 3.2.3 Global Targeted RNA Sequencing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Research Institutes
  • 4.1.2 Hospitals & Clinics
  • 4.1.3 Biotechnology Company
  • 4.1.4 Diagnostic Lab
• 4.2 Global Targeted RNA Sequencing Sales Value by Application
  • 4.2.1 Global Targeted RNA Sequencing Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Targeted RNA Sequencing Sales Value, by Application (2020-2031)
  • 4.2.3 Global Targeted RNA Sequencing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Targeted RNA Sequencing Sales Value by Region
  • 5.1.1 Global Targeted RNA Sequencing Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Targeted RNA Sequencing Sales Value by Region (2020-2025)
  • 5.1.3 Global Targeted RNA Sequencing Sales Value by Region (2026-2031)
  • 5.1.4 Global Targeted RNA Sequencing Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Targeted RNA Sequencing Sales Value, 2020-2031
  • 5.2.2 North America Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Targeted RNA Sequencing Sales Value, 2020-2031
  • 5.3.2 Europe Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Targeted RNA Sequencing Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Targeted RNA Sequencing Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Targeted RNA Sequencing Sales Value, 2020-2031
  • 5.5.2 South America Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Targeted RNA Sequencing Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Targeted RNA Sequencing Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Targeted RNA Sequencing Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.3.2 United States Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.4.2 Europe Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.5.2 China Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.6.2 Japan Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.7.2 South Korea Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.9.2 India Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Thermo Fisher
  • 7.1.1 Thermo Fisher Profile
  • 7.1.2 Thermo Fisher Main Business
  • 7.1.3 Thermo Fisher Targeted RNA Sequencing Products, Services and Solutions
  • 7.1.4 Thermo Fisher Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Thermo Fisher Recent Developments
• 7.2 Illumina
  • 7.2.1 Illumina Profile
  • 7.2.2 Illumina Main Business
  • 7.2.3 Illumina Targeted RNA Sequencing Products, Services and Solutions
  • 7.2.4 Illumina Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Illumina Recent Developments
• 7.3 Roche Holdings
  • 7.3.1 Roche Holdings Profile
  • 7.3.2 Roche Holdings Main Business
  • 7.3.3 Roche Holdings Targeted RNA Sequencing Products, Services and Solutions
  • 7.3.4 Roche Holdings Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Roche Holdings Recent Developments
• 7.4 BGI
  • 7.4.1 BGI Profile
  • 7.4.2 BGI Main Business
  • 7.4.3 BGI Targeted RNA Sequencing Products, Services and Solutions
  • 7.4.4 BGI Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.4.5 BGI Recent Developments
• 7.5 Eurofins
  • 7.5.1 Eurofins Profile
  • 7.5.2 Eurofins Main Business
  • 7.5.3 Eurofins Targeted RNA Sequencing Products, Services and Solutions
  • 7.5.4 Eurofins Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Eurofins Recent Developments
• 7.6 LabCorp
  • 7.6.1 LabCorp Profile
  • 7.6.2 LabCorp Main Business
  • 7.6.3 LabCorp Targeted RNA Sequencing Products, Services and Solutions
  • 7.6.4 LabCorp Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.6.5 LabCorp Recent Developments
• 7.7 Berry Genomics
  • 7.7.1 Berry Genomics Profile
  • 7.7.2 Berry Genomics Main Business
  • 7.7.3 Berry Genomics Targeted RNA Sequencing Products, Services and Solutions
  • 7.7.4 Berry Genomics Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Berry Genomics Recent Developments
• 7.8 Macrogen
  • 7.8.1 Macrogen Profile
  • 7.8.2 Macrogen Main Business
  • 7.8.3 Macrogen Targeted RNA Sequencing Products, Services and Solutions
  • 7.8.4 Macrogen Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Macrogen Recent Developments
• 7.9 GENEWIZ
  • 7.9.1 GENEWIZ Profile
  • 7.9.2 GENEWIZ Main Business
  • 7.9.3 GENEWIZ Targeted RNA Sequencing Products, Services and Solutions
  • 7.9.4 GENEWIZ Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.9.5 GENEWIZ Recent Developments
• 7.10 Natera
  • 7.10.1 Natera Profile
  • 7.10.2 Natera Main Business
  • 7.10.3 Natera Targeted RNA Sequencing Products, Services and Solutions
  • 7.10.4 Natera Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Natera Recent Developments
• 7.11 Novogen
  • 7.11.1 Novogen Profile
  • 7.11.2 Novogen Main Business
  • 7.11.3 Novogen Targeted RNA Sequencing Products, Services and Solutions
  • 7.11.4 Novogen Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Novogen Recent Developments
• 7.12 Pacific Biosciences
  • 7.12.1 Pacific Biosciences Profile
  • 7.12.2 Pacific Biosciences Main Business
  • 7.12.3 Pacific Biosciences Targeted RNA Sequencing Products, Services and Solutions
  • 7.12.4 Pacific Biosciences Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Pacific Biosciences Recent Developments
• 7.13 Oxford Nanopore
  • 7.13.1 Oxford Nanopore Profile
  • 7.13.2 Oxford Nanopore Main Business
  • 7.13.3 Oxford Nanopore Targeted RNA Sequencing Products, Services and Solutions
  • 7.13.4 Oxford Nanopore Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Oxford Nanopore Recent Developments

8 Industry Chain Analysis

• 8.1 Targeted RNA Sequencing Industrial Chain
• 8.2 Targeted RNA Sequencing Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Targeted RNA Sequencing Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Targeted RNA Sequencing Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer